Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Female sexual arousal disorder Stories

2014-03-31 16:27:19

CRANBURY, N.J., March 31, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has granted an extension until April 30, 2014 to an existing option agreement with a potential commercial partner for an exclusive license to bremelanotide for female sexual dysfunction indications in...

2014-02-24 08:27:59

Data from first-in-class investigational treatment presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Conference in San Diego CRANBURY, N.J., Feb. 24, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined...

2014-02-11 12:26:47

Women's Groups Call on FDA to Restore Gender Equity in the Treatment of Sexual Disorders WASHINGTON, Feb. 11, 2014 /PRNewswire-USNewswire/ -- In response to the U.S. Food and Drug Administration's (FDA) decision to further delay approval of the first-ever drug to treat the most common female sexual disorder, the National Consumers League and the National Organization for Women, joined by women's health and advocacy organizations, are calling on the FDA to move swiftly to end the 16...

2014-02-11 08:31:56

Agency Proposes Select Phase I Studies as Part of Resubmission RALEIGH, N.C., Feb. 11, 2014 /PRNewswire/ -- Sprout Pharmaceuticals announced today that their Formal Dispute Resolution, which was filed in December 2013, resulted in clear guidance from the FDA on the path forward. Sprout will resubmit the New Drug Application (NDA) for flibanserin, a once-daily treatment for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women, by the third quarter. The FDA has requested...

2014-02-04 12:27:27

ALMERE, The Netherlands, February 4, 2014 /PRNewswire/ -- On January 29th, 2014, Emotional Brain received the Scientific Advice letters from the European Medicines Agency (EMA) for the products Lybrido and Lybridos. The company is very pleased to announce that virtually all company proposals on the development plans for the two products were endorsed. Emotional Brain has adopted a personalized approach to medicine in the development of two drugs for the treatment of...

2014-01-30 08:31:26

CRANBURY, N.J., Jan. 30, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunctions will be presented at the 16(th) Congress of the European Society for Sexual Medicine in Istanbul, Turkey on Friday, January 31, 2014 at 3:25 PM local time. Dr. Michael L. Krychman from Southern California Center for...

2014-01-27 12:29:17

Nearly two-thirds of women polled believe it's inappropriate that the score is 24-0 when it comes to federal approval of treatments for desire, arousal or orgasm dysfunction in men vs. women WASHINGTON, Jan. 27, 2014 /PRNewswire-USNewswire/ -- Almost two-thirds of American women believe that society places a greater emphasis on addressing men's sexual satisfaction than on women's - an opinion underscored by the fact that 24 drugs have received federal approval to treat male sexual...

2014-01-26 23:02:25

Medical and Therapeutic Sexual Treatments for Men, Women and Couples New York, NY (PRWEB) January 26, 2014 According to the Journal of Sexual medicine, 16% of couples face constant sexual dysfunction in their relationship. Studies show that sexual issues facing couples are more effectively overcome when treating the couple rather than the individual. Dr. Jed Kaminetsky, a renown Manhattan-based Urologist, formed the Manhattan Sexual Health and Wellness (MSHW) to provide critical...

2013-12-17 08:28:37

ALMERE, The Netherlands, December 17, 2013 /PRNewswire/ -- Emotional Brain is a scientific research company engaged in the development (and implementation) of intelligent reasoning programs and medications directed at a personalized approach to healthcare. The foundation for this work is the premise that there exist individual differences in the causes of certain diseases. When different causal mechanisms can be elucidated for a physical or mental illness, more focused...

2013-11-13 16:27:00

CRANBURY, N.J., Nov. 13, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has entered into an option agreement for an exclusive license to bremelanotide for female sexual dysfunction indications in selected European countries, including the European Union. Palatin...